Everest Organics develops API for molnupiravir
The drug is being developed at lab scale for the first-line of treatment of Covid-19
The drug is being developed at lab scale for the first-line of treatment of Covid-19
Posaconazole is a triazole antifungal agent indicated for treating mucormycosis patients
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
Subscribe To Our Newsletter & Stay Updated